Visualising c-MET and Activated Neutrophils in Lung Cancer
NCT: NCT02676050 · TERMINATED
Brief Summary
Lung cancer is currently a major health problem in the UK. Despite being one of the most common cancers, lung cancer has a poor prognosis compared to other types of cancer and is the leading cause of cancer death in the world. As opposed to other organs, the lung is highly susceptible to inflammatory insults, for example from bacterial infection-induced and tobacco-induced inflammation. It has long been known that the cellular microenvironment that nurtures tumour growth and development is linked to sites of chronic inflammation but molecular insights into how external inflammation boosts or inhibits cancer in the lungs remains unclear. This study aims to directly visualise the expression of a well known marker of cancerous tissue, c-MET, and the activity of neutrophils in human lung cancer in vivo in situ using fibre-based endomicroscopy.
Frequently Asked Questions
What is Visualising c-MET and Activated Neutrophils in Lung Cancer?
Visualising c-MET and Activated Neutrophils in Lung Cancer is a clinical trial registered under NCT02676050. Current status: TERMINATED.
What is the status of NCT02676050?
The current status of NCT02676050 (Visualising c-MET and Activated Neutrophils in Lung Cancer) is: TERMINATED.
When did Visualising c-MET and Activated Neutrophils in Lung Cancer start?
Visualising c-MET and Activated Neutrophils in Lung Cancer started on 2019-10-04.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.